NEUP Neuphoria to merge with UK's Scancell in all-share deal, combined company heading to Nasdaq - Scancell shareholders end up owning
NEUP Neuphoria to merge with UK's Scancell in all-share deal, combined company heading to Nasdaq — Scancell shareholders end up owning ~85.5%, Neuphoria holders ~14.5% — Deal comes with up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+ — Neuphoria brings ~$1